Filing of J&J’s novel depression treatment expected in the coming months

Consumer

Johnson & Johnson’s esketamine nasal spray could be the first new drug in decades for patients with treatment-resistant major depression.

Compared to placebo, a clinically meaningful rapid reduction of depressive symptoms was produced when the nasal spray was combined with a newly initiated oral antidepressant in two Phase III clinical studies in patients with treatment-resistant depression.

“Johnson & Johnson’s esketamine nasal spray could be the first new drug in decades for patients with treatment-resistant major depression“

"With about 30% of patients with major depression failing to respond to currently available antidepressants, treatment-resistant depression represents a major public health need," said Husseini K. Manji, MD, Global Head, Neuroscience Therapeutic Area, Janssen Research & Development.

While the trial data wasn’t entirely conclusive, the high unmet need in the area is likely to persuade approval for the treatment. Data from other Phase III studies will be presented later this year.

See all the latest jobs in Consumer
Return to news